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Abstract Prediction of long-term disability in patients
with multiple sclerosis (MS) is essential. Magnetic reso-
nance imaging (MRI) measurement of brain volume may
be of predictive value but sophisticated MRI techniques are
often inaccessible in clinical practice. The corpus callosum
index (CCI) is a normalized measurement that reflects
changes of brain volume. We investigated medical records
and 533 MRI scans at diagnosis and during clinical follow-
up of 169 MS patients (mean age 42 ± 11 years, 86%
relapsing-remitting MS, time since first relapse 11 ±
9 years). CCI at diagnosis was 0.345 ± 0.04 and correlated
with duration of disease (p = 0.002; r = -0.234) and
expanded disability status scale (EDSS) score at diagnosis
(r = -0.428; p \ 0.001). Linear regression analyses
identified age, duration of disease, relapse rate and EDSS at
diagnosis as independent predictors for disability after
mean of 7.1 years (Nagelkerkes’ R:0.56). Annual CCI
decrease was 0.01 ± 0.02 (annual tissue loss: 1.3%). In
secondary progressive MS patients, CCI decrease was
double compared to that in relapsing-remitting MS patients
(p = 0.04). There was a trend of greater CCI decrease in
untreated patients compared to those who received disease
modifying drugs (p = 0.2). CCI is an easy to use MRI
marker for estimating brain atrophy in patients with MS.
Brain atrophy as measured with CCI was associated with
disability progression but it was not an independent pre-
dictor of long-term disability.
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Introduction
Prediction of long-term disability in patients with multiple
sclerosis (MS) is important for both patients and physicians.
Several studies have been conducted to identify clinical
characteristics such as relapse rate, gender or age in an
attempt to predict long-term disability, although correla-
tions were only modest [6, 36, 42]. Despite initial disease
course (i. e. relapse rate) and early disability evolution (as
measured by the expanded disability status scale, or EDSS)
being of some prognostic value, long-term progression
remains largely unpredictable. This uncertainty stresses the
need for reliable para-clinical parameters such as magnetic
resonance imaging (MRI). MRI techniques play an impor-
tant role and can depict subclinical disease progression. The
most established MRI parameters used in evaluating disease
outcome and routinely used in clinical trials are hyper-
intensities on T2 weighted images, hypo-intensities in T1
weighted images and contrast enhancing lesions [22, 33, 48,
50]. However, several studies have revealed only a weak
correlation between T2 lesion load and clinical disability
[14, 16, 17, 35, 37]. New MRI techniques have been
developed that offer the prospect of greater specificity
including measurements of brain volume [12, 28, 30].
Sophisticated MRI techniques are laborious, need special
software and are often inaccessible in clinical practice. In
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search of more practical bedside parameters the corpus
callosum index (CCI) has been suggested as a marker for
brain atrophy in MS patients [11]. Demonstrated correlation
of CCI and atrophy has been measured with brain paren-
chymal fraction. In addition, CCI correlates with cognitive
impairment in relapsing-remitting MS (RRMS) and sec-
ondary progressive MS (SPMS) patients. The corpus cal-
losum is the largest compact white matter fiber bundle of the
brain connecting both hemispheres [23]. Previous MRI and
histopathological studies have consistently revealed the
corpus callosum as one of the sites most commonly affected
by demyelination and axonal loss [2, 10, 20, 32, 38, 45]. The
aim of this study was to investigate the relationship between
CCI and long-term disability evolution in MS.
Patients and methods
Study design
This study is a cohort study of RRMS and SPMS patients
based on an analysis of medical records and on serial MRI
examinations from which a linear measurement (CCI) was
retrospectively calculated.
Patients
From October 2008 to April 2009, we screened all patients
attending our MS outpatient clinic. Inclusion criteria were
patients between 18 and 60 years at presentation, diagnosis
of relapsing-remitting MS (RRMS) according to revised
McDonald criteria 2005 [39] or secondary progressive MS
(SPMS) [31] and availability of at least one MRI exami-
nation performed in our radiological institute. Exclusion
criteria were any brain pathology other than MS, pure spinal
manifestation of demyelination, neuromyelitis optica and
primary progressive MS (PPMS). We excluded PPMS
patients because only a limited number were followed at our
center. Clinical characteristics were derived from medical
records. Disease duration was defined as time since first
manifestation of disease. Relapses were defined as the
development of new or recurrent neurological symptoms
not associated with fever or infection lasting at least 24 h
and confirmed by a Swiss or German board-certified neu-
rologist. Secondary progression was defined as continued
deterioration of disability for at least 12 months with or
without interposed relapses after an initial relapsing-
remitting course of disease [31]. Patients were not part of a
clinical trial. Most patients were treated with disease
modifying drugs. The reasons for patients being untreated
or untreated during certain periods were due to previous
side effects or a personal decision. Patients were regarded as
untreated if cumulative treatment duration was\3 months.
MRI analysis
All MRI scans were performed in our radiological institute
(1.5 Tesla Sigma Magnetom Scanner, Siemens AG, Ger-
many) and included the following: an axial pre and post
gadolinium T1 weighted, sagittal T1 weighted and fluid
attenuated inversion recovery sequence (FLAIR), axial T2
weighted and axial FLAIR sequences. All MRI scans were
analyzed by the same examiner (OY). For reliability
analysis, CCI of 266 MRI scans were measured indepen-
dently by two additional investigators (RA, SG). All raters
were blind to patient clinical data at assessment. The
concordance rate among the three investigators was 0.93
(Cronbach alpha). Both T2 and T1 lesion load and contrast
enhancement were determined by Swiss board-certified
radiologists. T2 lesion load was dichotomized as either\9
T2 lesions or C9 T2 lesions. T1 lesions and contrast
enhancing lesions were categorized as present or absent.
CCI was obtained on conventional best mid-sagittal T1
weighted images by drawing a line at the greatest antero-
posterior diameter of the corpus callosum and a perpen-
dicular line at its midpoint (Fig. 1). T1 weighted images
are chosen because of the higher signal and contrast to
noise ratio [11]. The measurements have been performed
on a picture archiving and communication system (PACS)
workstation and if unavailable directly on films. The best
mid-sagittal image was found by identification of the
middle part of the fornix. Anterior, posterior and medium
segments of the corpus callosum were measured and nor-
malized to its greatest antero-posterior diameter with an
electronic calliper or by computerized measurement tool on
screen. The concordance rate of electronic calliper and
on-screen measurement was 0.97 based on 189 MRI scans
from 71 patients. Higher CCI values indicate a higher
corpus callosum volume.
Statistical analysis
Demographic data are presented as mean ± standard
deviation. For comparison of continued variables we used
the Mann–Whitney test for independent samples. Reli-
ability was assessed as Cronbach alpha. Correlation anal-
yses including CCI, age, disease duration, MRI parameters
and EDSS were performed with the non-parametric rank
correlation analysis Spearman-Rho and an adjusted sig-
nificance level of 0.005 (p = 0.05/10; Bonferroni correc-
tion). A backward directed linear regression analysis was
performed to identify best predictors for disability status
(last EDSS). Last EDSS was used as an outcome measure
(continued variable). The potential predictors were CCI at
diagnosis (continued variable), age (continued variable),
duration of disease (continued variable), total number of
relapses (continued variable), total number of steroid
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pulses (continued variable), T2 lesion load (categorical
variable: \9/C9), gadolinium enhancement (categorical
variable: yes/no), EDSS at diagnosis (continued variable)
and course of disease (categorical variable: RRMS/SPMS).
We used SPSS (Windows version 14; SPSS, Chicago, IL)
for all statistical analysis.
Results
We screened 176 consecutive patients. Excluded from the
analysis were one patient with hydrocephalus due to con-
genital aqueduct stenosis, one patient with concomitant
idiopathic epilepsy and five patients with isolated spinal
demyelination. Thus, this analysis comprised data of 169
MS patients. We investigated medical records and all
available MRI scans (n = 533; 3.2 ± 1.7 MRIs per
patient). Corresponding EDSS data (assessed within
2 months of MRI) were available at 388 time points. The
demographic characteristics of patients are given in
Table 1 and the results from correlation analyses in
Table 2.
CCI at diagnosis was 0.345 ± 0.04 and correlated with
disease duration and EDSS at diagnosis. CCI at diagnosis
did not correlate with age at presentation, age at first
manifestation, gadolinium enhancing lesions at diagnosis,
T1 or T2 lesion load at diagnosis or gender. EDSS at
diagnosis was 2.6 ± 0.7 and correlated with course of
disease, disease duration and T1 lesions (p = 0.002; EDSS
2.1 ± 1.2 in the group without T1 lesions versus
3.05 ± 1.7 in the group with T1 lesions). EDSS at diag-
nosis did not correlate with gender, gadolinium enhance-
ment at diagnosis, T2 lesion load (\9/C9) or age at first
Fig. 1 MRI of a 31 year old male patient with first diagnosis
of RRMS (Fig. 1; EDSS 1.5; CCI = 0.321) and follow-up
4 years later (Fig. 2; EDSS 4.0; CCI = 0.259). CCI is calculated as
(aa0 ? bb0 ? cc0)/ab0. Lower CCI values indicate a lower corpus
callosum volume. CCI decrease of 20% in 4 years was associated
with an increase of EDSS from 1.5 to 4.0. (CCI corpus callosum index
EDSS expanded disability status scale, RRMS relapsing-remitting
multiple sclerosis)
Table 1 Demographic data
Patient characteristics
n 169
Age (years ± SD) 42.0 ± 11.3
Gender (%)
Male 43 (25.4)
Female 126 (74.6)
Course of disease (%)
RRMS 145 5.8)
SPMS 24 (14.2)
Time from first manifestation to diagnosis (years) 3.9 ± 3.0
Duration (years ± SD) since first manifestation of
disease
10.9 ± 8.8
EDSS at diagnosis 2.6 ± 0.7
Last EDSSa 2.97 ± 0.86
T2 lesion load at diagnosis (%)
\9 74 (6.8)
C9 95 (56.2)
T1 lesions at diagnosis (%)
No 99 (58.6)
Yes 70 (41.4)
Contrast enhancement at diagnosis (%)
No 134 (9.3)
Yes 23 (13.6)
No gadolinium applied 12 (7.1)
Total number of relapses including first event 4.2 ± 1.8
Total n/o steroid pulse therapies 2.3 ± 1.0
Disease modifying therapy (%)
Never 22 (13.0)
Yes (at any time) 147 (87.0)
Median treatment duration (range; years) 4.0 (0.2–
23.75)
Currently on treatment 118 (69.8)
RRMS relapsing-remitting multiple sclerosis, SPMS secondary pro-
gressive multiple sclerosis, EDSS expanded disability status scale
a mean follow-up 7.1 ± 6.4 (median 5.2; 0.2–33.2 years)
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manifestation. After a mean time follow-up of 7.1 ±
6.4 years (median 5.2 years; range 0.2–33.27 years) CCI
decreased from 0.345 ± 0.04 to 0.317 ± 0.03 by a mean
of 0.01 ± 0.02 per year, whereas EDSS increased from
2.6 ± 0.7 to 2.97 ± 0.86 (last EDSS). EDSS worsened in
49 patients (27.4%) by at least one point over the obser-
vational period. Last EDSS correlated with CCI at diag-
nosis, CCI at last MRI, age at time of study, disease
duration, EDSS at diagnosis, number of relapses, number
of steroid pulse therapies and course of disease (2.61 ±
1.36 in the RRMS group vs. 5.07 ± 2.15 in the PPMS
group; p \ 0.001). Last EDSS did not correlate with age at
first manifestation of disease, T1 lesion load at diagnosis,
T2 lesion load at diagnosis or gadolinium positive lesions
at diagnosis or treatment with disease modifying drugs
(DMD) (Table 2).
We conducted a linear regression analysis with last
EDSS as a dependent variable and with CCI at diagnosis,
age today, disease duration, total number of relapses, total
number of steroid pulses, T2 lesion load at diagnosis,
presence of gadolinium positive lesion, EDSS at diagnosis
and course of disease as covariates. This analysis revealed
EDSS at diagnosis, disease duration, age today and number
of relapses as independent predictors for the last EDSS
(Nagelkerkes’ R: 0.56, Table 3).
Twenty-four patients (17 female, 7 male) had secondary
progression after a mean duration of 6.2 ± 4.6 years.
These patients had lower CCI values at diagnosis
(p = 0.003) compared to those without secondary pro-
gression (0.308 ± 0.08 in SPMS vs. 0.353 ± 0.06 in
RRMS patients). In SPMS patients, annual CCI decrease
was higher than in RRMS patients (CCI reduction in RMS
patients -0.006 ± 0.015 versus -0.02 ± 0.011; p = 0.04,
Fig. 2). We saw in patients with T2 lesion load C9, T1
hypo-intensities or contrast enhancing lesions at first
examination a trend of greater and earlier CCI decrease,
Table 2 Correlation analyses of corpus callosum index (CCI) at diagnosis and expanded disability status scale (EDSS) at diagnosis and after
mean of 7.1 years (last EDSS)
Correlations Significance; r value
CCI at diagnosis versus Duration of disease based on first manifestation p = 0.002; r = -0.234
EDSS at diagnosis p \ 0.001; r = -0.428
n.s.Age at time of the study
Age at first manifestation n.s.
Gd positive lesion at diagnosis n.s.
T1 lesion at diagnosis n.s.
T2 lesion at diagnosis n.s.
Gender n.s.
EDSS at diagnosis versus Course of disease (RRMS/SPMS) p = 0.001
Disease duration since first manifestation of disease p \ 0.001; r = 0.456
Presence of T1 lesion(s) at diagnosis p = 0.002
Gender n.s.
Gd positive lesions n.s.
T2 lesion load (\9/C9) n.s.
Age at first manifestation n.s.
Last EDSS versus CCI at diagnosis p = 0.002; r = 0.283
CCI at last MRI p \ 0.001; r = 0.301
Age at time of study p \ 0.001; r = 0.392
Duration of disease since first manifestation p \ 0.001; r = 0.496
EDSS at diagnosis p \ 0.001; r = 0.436
Number of relapses p \ 0.001; r = 0.301
Number of steroid pulse therapies p \ 0.001; r = 0.3
Course of disease (RRMS vs. SPMS) p \ 0.001
Age at first manifestation of disease n.s.
T1 lesion load at diagnosis n.s.
T2 lesion load at diagnosis n.s.
Gd positive lesions at diagnosis n.s.
Treatment with disease modifying drugs n.s.
RRMS relapsing-remitting MS, SPMS secondary progressive MS, Gd Gadolinium, n.s. not significant
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defined as time between first and second MRI after a mean
of 2.5 ± 1.5 years (p = 0.07; data not shown) without
reaching significance.
Eighty-seven percent of patients (n = 147) received
DMDs (mean treatment duration 3.98 ± 0.15 years (med-
ian 4.0 years, range 0.2–23.75 years). Baseline character-
istics of patients with and without DMD treatment are
given in Table 4. Twenty-two patients were not treated
with DMDs. They were more likely to have secondary
progressive MS (p = 0.02), higher annualized relapse rate
and more common gadolinium positive lesions on baseline
MRI. Patients treated with and without DMDs did not
differ in terms of sex, age, disease duration, T2 or T1
lesions at diagnosis, CCI or EDSS at diagnosis or last visit,
number of relapses or number of steroid pulse therapies.
Annual CCI decrease was three times higher in patients
without DMD (-0.0174 ± 0.018; n = 22) compared to
patients who received DMD (-0.005 ± 0.014 per year;
n = 147; p = 0.2).
Discussion
Brain atrophy and long-term disability
The main finding of our study was that brain atrophy as
measured by CCI was associated with disability progres-
sion in MS patients. However, CCI was not an independent
predictor of long-term disability. Our analysis revealed that
about 56% of the variance of future disability is predicted
by age of the patient at presentation, duration of disease,
number of relapses and EDSS at diagnosis of MS, the latter
being the best predictor for future disability.
Our results for brain atrophy as measured with CCI are
in line with other investigations using more sophisticated
MRI methods for evaluation of brain atrophy such as brain
parenchymal fraction (BPF). Several studies indicate a
strong relationship between brain atrophy and EDSS [9, 27,
44] or disease duration [3, 18, 21, 27, 43, 44]. A cross-
sectional study of 90 MS-patients [9] demonstrated that
EDSS correlated with neo-cortical volume both in 65
RRMS and 25 PPMS patients (r = -0.27 to r = -0.64,
p \ 0.05). Another study [27] found in 33 MS patients a
lower brain parenchymal fraction (BPF) compared with
age-matched controls. BPF correlated with disease duration
and EDSS (r = -0.51, p \ 0.05) but not with the number
of detectable MS lesions.
On the other hand, several studies have failed to find a
significant correlation between brain atrophy and disability
[4, 13, 15, 18, 26, 40, 47]. One such study could not find a
correlation among EDSS, age and BPF (n = 30) [18]. In
another study, an assessment of whole brain, grey matter
and white matter atrophy by quantitative MRI in 26 MS
patients found no correlations between EDSS and any
lesion type or fractional tissue volume [4].
The authors have advanced different arguments to
explain these contradictory results. Some authors have
discussed EDSS as an inappropriate score to estimate a
full range of impairment since cognitive dysfunction is
Table 3 Linear regression analysis using last expanded disability status scale (EDSS) as a dependent variable and age at first manifestation of
disease, relapse rate, number of steroid pulses, T2 lesion load, T1 lesion load and corpus callosum index (CCI) as covariates
Coefficient Standard error Standardized coefficient beta T-value p value
Constant -0.680 0.539 -1.261 0.211
Age 0.039 0.013 0.257 3.057 0.003
Duration of disease 0.108 0.028 0.383 3.787 0.000
Total number of relapses 0.152 0.059 0.201 2.560 0.012
EDSS at diagnosis 0.273 0.112 0.236 2.437 0.017
Fig. 2 Box-and-whisker diagram of the corpus callosum index (CCI)
change after a mean time of 7 years from baseline (1.0), relapsing-
remitting multiple sclerosis (RRMS) versus secondary progressive
multiple sclerosis (SPMS)
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not adequately represented [13]. Significant negative
correlations between upper cervical cord volume and
EDSS have been found, suggesting that higher EDSS
scores seem to correlate more with spinal than cerebral
manifestation of disease [29]. Other studies included
patients with only mild disability, restricting the potential
for detecting meaningful correlations [4, 26, 47]. Studies
have also investigated heterogeneous MS groups with a
short follow-up period [15]. Our study and the time series
follow-up data it generated over 7 years may have made
it easier to detect correlations between atrophy and
disability.
Lesion load and brain atrophy
We found a weak correlation among presence of T1
lesions, contrast enhancement and atrophy (CCI) while T2
lesion load did not correlate with CCI. The relationship
between lesion load and brain atrophy is discussed con-
troversially in the literature. One study found significant
correlations with r values reaching -0.78 for T2 lesion
volume and -0.59 for T1 lesion volume (RRMS only) [4].
Another study failed to find correlations between BPF and
lesion load [3, 4, 19] but this included patients with both
RRMS and SPMS as was the case in our study. A strong
Table 4 Patient and disease characteristics in patients exposed to DMD (C3 months) and untreated patients
Parameters DMD Significance
No Yes
n 22 147
Sex (%)
Male 4 (18.2) 39 (26.5) 0.40
Female 18 (81.8) 108 (73.5)
Age (years)
At time of study 43.5 ± 20.1 41.1 ± 12.3 0.12
At first manifestation 29.8 ± 23.3 30.6 ± 12.4 0.49
Disease duration (years) 13.8 ± 11.0 10.4 ± 8.3 0.24
Course of disease 0.02
RRMS 15 (68.2) 130 (88.4)
SPMS 7 (31.8) 17 (11.6)
T2 lesion load at diagnosis 0.53
\ 9 11(50) 63 (42.9)
C9 11 (50) 84 (57.1)
T1 lesions at diagnosis 0.61
No 14(63.6) 85 (57.8)
Yes 8 (36.4) 62 (42.2)
Gd positive lesion at diagnosisa 0.03
No 20 (100) 114 (3.2)
Yes 0 (0) 23 (16.8)
CCI
At diagnosis 0.342 ± 0.058 0.347 ± 0.069 0.68
At last visitb 0.306 ± 0.067 0.317 ± 0.077 0.51
EDSS
At diagnosis 3.4 ± 2.1 2.4 ± 1.3 0.23
At last visitb 3.6 ± 2.3 2.9 ± 1.6 0.25
Number of relapsesc 2.85 ± 1.8 4.38 ± 3.7 0.13
Number of steroid pulse therapies 1.23 ± 1.1 1.95 ± 2.1 0.30
Annualized relapse rate 1.13 ± 2.8 0.87 ± 1.3 0.03
DMD disease modifying drug RRMS relapsing-remitting MS SPMS secondary progressive MS Gd Gadolinium CCI corpus callosum index EDSS
expanded disability status scale
a Not every patient received gadolinium (see Table 1)
b Last visit was after mean of 7.1 years
c Number of relapses since first demyelinating event
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negative correlation between T2 lesion volume and base-
line BPF of 138 RRMS patients has been previously
shown, while a weak correlation was found between the
change in BPF over 3 months and T2 lesion volume at
baseline [21]. This suggested that lesion load is only a
weak predictor of progressive brain atrophy, a finding
similar to our results. In another study the baseline T2
lesion volume indicated more pronounced atrophy (BPF)
but T2 lesion volume accounted for only 8.2% of the
variance in progressive brain atrophy [41]. Some authors
have reported that grey matter volume rather than white
matter volume is correlated with total T2 or T1 lesion
volume [4, 18, 21, 24, 40, 43, 46, 49]. This would also
explain the weak correlation in our study.
Corpus callosum atrophy in different courses of disease
In our study, CCI decreased by approximately 9% over
approximately 7 years. This change reflects an annual
tissue loss of 1.3% and is consistent with other studies
using BPF method (0.5–1.3% annual brain volume loss)
[1, 5, 8, 21]. These findings have been demonstrated
elsewhere, underlining the remarkable correlation of the
easy bedside test CCI and BPF [11]. CCI decrease was
more than double in SPMS patients compared to RRMS
patients. CCI reduction in SPMS patients was similar to
results from a separate study [11]. Some studies have
reported reduced whole brain volumes in patients with
SPMS compared with age-matched RRMS patients [3, 19,
44, 51]. One such study measured white matter and grey
matter atrophy using a fully automated multi-parametric
segmentation method in 597 MS patients and found more
atrophy of both white and grey matter in SPMS patients
[46]. Another study reported that normalized brain vol-
ume was lower in 18 patients with SPMS (1,406 ml) than
in 36 RRMS patients (1,473 ml) [51]. Researchers
detected higher rates of brain parenchymal loss in 9
SPMS patients than in 27 RRMS patients (-1.5% per
year for RRMS vs. -2.0% per year for SPMS) [19].
Other studies found the periventricular region sensitive to
brain atrophy in SPMS patients. For example, in a cohort
of 83 patients with MS, researchers analyzed the rate of
brain volume loss over time using BPF as a measure of
whole brain atrophy and normalized ventricular volume as
a measure of central atrophy [26]. They reported that the
annualized rate of brain parenchymal atrophy did not
significantly differ between subtypes of patients (0.7%
per year), whereas the annualized rate of ventricular
enlargement was higher for SPMS patients. This result
was independently confirmed through an investigation of
ventricular enlargement over 1 year [7]; ventricular
enlargement in all MS patients over the 1 year period was
reported, but significantly greater enlargement occurred in
the SPMS group. A difference in the brain atrophy rate
between subgroups of MS has also been found, with the
largest decrease (0.9% per year) in patients with SPMS
and the smallest (0.6% per year) in patients with PPMS
[15]. These differences were very close to the rate
reported by others [26].
Disease modifying treatment and brain atrophy
DMDs are the mainstays of long-term therapy of MS. They
may decelerate brain volume loss by reducing inflamma-
tion and possibly promoting remyelination. Brain volume
loss can occur in every stage of disease, but is probably
more accentuated with longer disease duration and/or
SPMS. Although brain atrophy as measured with CCI was
three times higher in untreated patients, it did not reach
statistical significance. Several confounders could impact
this finding (e.g. disease type) and the low number of
untreated patients makes it hard to produce definitive
conclusions. It was demonstrated that DMDs may impact
atrophy but findings for the different preparations were
controversial [25, 41, 52].
Future studies should include either CCI or parameters
of corpus callosum volumetry to define effects of DMDs on
the parameter of brain atrophy.
Limitations of our study
The retrospective evaluation of the clinical course and the
measurement of only white matter atrophy represent
limitations of our study. Recent studies revealed that grey
matter atrophy is associated with disability. Segmentation
techniques have made it possible to distinguish between
grey matter and white matter [34]. Further studies should
combine linear measurement systems for grey and white
matter. Our study population was representative of the
population treated in our outpatient department (i. e. 86%
RRMS and 14% SPMS). We excluded patients with
concomitant brain pathology and patients without brain
lesions to enhance the reliability of our data. Most of our
patients (87%) were exposed to DMDs and had mild
disability after 7 years. The strengths of our study were
the long follow-up period and blinded MRI assessment.
CCI was a reliable MRI measurement with an interrater
reliability of more than 90%, which is similar to previ-
ously published data [11]. EDSS assessment was per-
formed by experienced neurologists who were certified
for undertaking such assessments in clinical trials. Recent
studies compared CCI with matched healthy controls [11].
Despite intersubject variations in the shape and size of
corpus callosum including sex differences and handed-
ness, our results show that CCI seems to be a robust
parameter.
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Conclusion
Brain atrophy as measured by CCI is an important marker of
subclinical disease course. CCI is easy to apply and correlates
with long-term disability. When sophisticated MRI parame-
ters of atrophy are not accessible, estimation of atrophy by
CCI may be included either for follow-up evaluations
alongside more established clinical (relapse rate, EDSS) and
para-clinical assessments (presence of Gd lesions, T2 lesion
load, presence of T1 lesions etc.) or may be applied toward a
more comprehensive risk model for the individual. However,
it needs to be noted that CCI did not represent an independent
predictor of disability in this study. Further investigations
should be performed prospectively, combining CCI with
linear measurements of grey matter (e.g. intercaudate ratio) to
better define a role in daily practice.
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